IRON
Disc Medicine, Inc.
$69.70
-0.33
(-0.47%)
Mkt Cap
2.66B
Volume
554,901
52W Range
40-99.5
Sector
Healthcare
Beta
2.14
EPS (TTM)
-6.64
P/E Ratio
-13.21
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (212.18M) | (109.36M) | (76.43M) | (46.83M) | (35.97M) | (40.84M) |
| EPS | -6.01 | -3.96 | -3.42 | -45.05 | -44.88 | -27.02 |
| Free Cash Flow | (181.33M) | (94.43M) | (73.55M) | (42.40M) | (27.60M) | (32.73M) |
| FCF / Share | -5.14 | -3.42 | -3.30 | -40.79 | -34.44 | -21.65 |
| Operating CF | (180.39M) | (93.93M) | (73.46M) | (42.25M) | (27.53M) | (32.71M) |
| Total Assets | 806.88M | 496.77M | 368.00M | 200.21M | 92.41M | 8.32M |
| Total Debt | 1.86M | 30.00M | 2.10M | 1.33M | 7.06M | 21.64M |
| Cash & Equiv | 91.14M | 192.43M | 360.38M | 194.61M | 88.04M | 4.50M |
| Book Value | 739.83M | 443.59M | 345.12M | 176.60M | (64.20M) | (21.86M) |
| Return on Equity | -0.29 | -0.25 | -0.22 | -0.27 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (63.50M) | (60.53M) | (62.32M) | (55.25M) | (34.09M) | (29.46M) | (26.60M) | (26.35M) | (26.95M) | (23.58M) | (14.12M) | (15.95M) |
| EPS | -1.65 | -1.64 | -1.77 | -1.58 | -1.02 | -0.98 | -0.89 | -1.03 | -1.09 | -1.00 | -0.58 | -0.74 |
| Free Cash Flow | (62.24M) | (43.32M) | (47.83M) | (47.95M) | (42.23M) | (28.02M) | (17.35M) | (15.39M) | (33.67M) | (17.80M) | (7.52M) | (12.74M) |
| FCF / Share | -1.62 | -1.23 | -1.36 | -1.37 | -1.27 | -0.94 | -0.58 | -0.60 | -1.36 | -0.76 | -0.31 | -0.59 |
| Operating CF | (62.24M) | (43.30M) | (47.80M) | (47.92M) | (41.38M) | (27.57M) | (17.36M) | (15.39M) | (33.60M) | (17.80M) | (7.48M) | (12.72M) |
| Total Assets | 750.21M | 806.88M | 630.46M | 665.06M | 709.27M | 496.77M | 495.14M | 510.22M | 354.18M | 368.00M | 376.50M | 384.17M |
| Total Debt | 31.06M | 1.86M | 30.98M | 30.92M | 30.64M | 30.00M | 1.79M | 1.84M | 2.03M | 2.10M | 1.96M | 2.09M |
| Cash & Equiv | 88.91M | 91.14M | 140.66M | 127.34M | 122.67M | 192.43M | 192.64M | 280.66M | 342.62M | 360.38M | 370.54M | 377.60M |
| Book Value | 688.43M | 739.83M | 573.39M | 614.16M | 660.36M | 443.59M | 467.96M | 488.83M | 338.07M | 345.12M | 358.97M | 371.22M |
| Return on Equity | -0.09 | -0.08 | -0.11 | -0.09 | -0.05 | -0.07 | -0.06 | -0.05 | -0.08 | -0.07 | -0.04 | -0.04 |
IRON News
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
Disc Medicine to Participate in Upcoming Investor Conferences
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc. - IRON